Abstract
Angiotensin-converting enzyme (ACE) inhibitors have been very successful in patients with vascular disease, in particular for hypertension, left ventricular dysfunction and vascular protection. Angiotensin receptor blocking drugs (ARBs) were developed later and differ from ACE inhibitors in several ways. We are now beginning to see the results of large studies of ARBs in high-risk patients and some head-to-head comparisons between these two classes of drugs which reduce the actions of angiotensin II. This review considers these trials under the headings of heart failure, hypertension, renal function, and high-risk cardiovascular disease/coronary heart disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
